Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Inclusion Criteria: * Age at 18-75 years. * Documented evidence of NSCLC (locally advanced, unresectable, Stage III) * Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) * Eastern Cooperative Oncology Group performance status score (ECOG PS) of 0 to 1. * Estimated life expectancy of more than 12 weeks. Exclusion Criteria: * Prior exposure to any anti-PD-1 or anti-PD-L1 antibody. * Active or prior autoimmune disease or history of immunodeficiency. * Evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses or active infections including hepatitis B, C and HIV. * Evidence of uncontrolled illness such as symptomatic congestive heart failure, uncontrolled hypertension or unstable angina pectoris. * Any unresolved toxicity CTCAE \>Grade 2 from the prior chemoradiation therapy. * Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).